about
Current knowledge on the sensitivity of the (68)Ga-somatostatin receptor positron emission tomography and the SUVmax reference range for management of pancreatic neuroendocrine tumoursInfluence of biological assay conditions on stability assessment of radiometal-labelled peptides exemplified using a 177Lu-DOTA-minigastrin derivative.Developing Targeted Hybrid Imaging Probes by Chelator ScaffoldingInfluence of a novel, versatile bifunctional chelator on theranostic properties of a minigastrin analogue.Influence of PEGylation and RGD loading on the targeting properties of radiolabeled liposomal nanoparticles.Preclinical pharmacokinetics, biodistribution, radiation dosimetry and toxicity studies required for regulatory approval of a phase I clinical trial with (111)In-CP04 in medullary thyroid carcinoma patientsTumor targeting and imaging with dual-peptide conjugated multifunctional liposomal nanoparticles.177Lu Labeled Cyclic Minigastrin Analogues with Therapeutic Activity in CCK2R Expressing Tumors: Preclinical Evaluation of a Kit Formulation.Methoxinine - an alternative stable amino acid substitute for oxidation-sensitive methionine in radiolabelled peptide conjugates.Preclinical evaluation of radiolabeled DOTA-derivatized cyclic minigastrin analogs for targeting cholecystokinin receptor expressing malignancies.Targeting properties of peptide-modified radiolabeled liposomal nanoparticles.Comparison of the binding and internalization properties of 12 DOTA-coupled and ¹¹¹In-labelled CCK2/gastrin receptor binding peptides: a collaborative project under COST Action BM0607.[68Ga]NODAGA-RGD for imaging αvβ3 integrin expression.Intracellular signaling pathways regulating radioresistance of human prostate carcinoma cells.99mTc-labeling and in vitro and in vivo evaluation of HYNIC- and (Nalpha-His)acetic acid-modified [D-Glu1]-minigastrin.Automated synthesis of an 18F-labelled pyridine-based alkylating agent for high yield oligonucleotide conjugation.In vitro characterization of two novel biodegradable vectors for the delivery of radiolabeled antisense oligonucleotides.Radiolabeling of lipid-based nanoparticles for diagnostics and therapeutic applications: a comparison using different radiometals.99mTc-EDDA/HYNIC-TOC and (18)F-FDG in thyroid cancer patients with negative (131)I whole-body scans.Cyclic minigastrin analogues for gastrin receptor scintigraphy with technetium-99m: preclinical evaluation.Comparison of different methods for radiochemical purity testing of [99mTc-EDDA-HYNIC-D-Phe1,Tyr3]-octreotide.99mTc-N4-[Tyr3]Octreotate Versus 99mTc-EDDA/HYNIC-[Tyr3]Octreotide: an intrapatient comparison of two novel Technetium-99m labeled tracers for somatostatin receptor scintigraphy.Early dynamic imaging in 68Ga- PSMA-11 PET/CT allows discrimination of urinary bladder activity and prostate cancer lesions.68Ga-PSMA-11 PET/CT in primary staging of prostate cancer: PSA and Gleason score predict the intensity of tracer accumulation in the primary tumour.Early PET imaging with [68]Ga-PSMA-11 increases the detection rate of local recurrence in prostate cancer patients with biochemical recurrence.A fully automated synthesis for the preparation of 68Ga-labelled peptides.Site-specific stabilization of minigastrin analogs against enzymatic degradation for enhanced cholecystokinin-2 receptor targeting.Exploiting the Concept of Multivalency with 68Ga- and 89Zr-Labelled Fusarinine C-Minigastrin Bioconjugates for Targeting CCK2R Expression.Albumin-based nanoparticles as magnetic resonance contrast agents: I. Concept, first syntheses and characterisationMultimerization results in formation of re-bindable metabolites: A proof of concept study with FSC-based minigastrin imaging probes targeting CCK2R expressionComparison of [68Ga]Ga-PSMA-11 PET/CT with [18F]NaF PET/CT in the evaluation of bone metastases in metastatic prostate cancer patients prior to radionuclide therapy99mTc-labelled HYNIC-minigastrin with reduced kidney uptake for targeting of CCK-2 receptor-positive tumours68Ga-DOTA-Tyr3-Octreotide PET in Neuroendocrine Tumors: Comparison with Somatostatin Receptor Scintigraphy and CTMultiparametric PET imaging in thyroid malignancy characterizing tumour heterogeneity: somatostatin receptors and glucose metabolismCholecystokinin-2 Receptor Targeting with Novel C-terminally Stabilized HYNIC-Minigastrin Analogs Radiolabeled with Technetium-99mA novel CCK2/gastrin receptor-localizing radiolabeled peptide probe for personalized diagnosis and therapy of patients with progressive or metastatic medullary thyroid carcinoma: a multicenter phase I GRAN-T-MTC studyDOTA-MGS5, a New Cholecystokinin-2 Receptor-Targeting Peptide Analog with an Optimized Targeting Profile for Theranostic UseErratum: Site-specific stabilization of minigastrin analogs against enzymatic degradation for enhanced cholecystokinin-2 receptor targeting: ErratumCorrection: Klingler, M., et al. Cholecystokinin-2 Receptor Targeting with Novel C-terminally Stabilized HYNIC-Minigastrin Analogs Radiolabeled with Technetium-99m. Pharmaceuticals 2019, 12, 13Comparison of PEGylated and non-PEGylated proticles: An in vitro and in vivo study
P50
Q28071483-6EBFAFAC-9797-47DB-89B1-492DC54DEF82Q33818847-C2B50C0F-C101-4228-BF21-DA95A725152BQ33827092-6BA79D70-0BD6-42E0-89C7-DABB041618F4Q36373488-1963F6AA-E588-4D61-AECD-4C80CFDA816EQ36440766-8D0E41E9-9322-43B0-923B-512341307F28Q37103342-F34FCCF8-EEA4-4D3F-800F-5F5E29F753B2Q37390746-50ACB315-EEA8-48D7-84B4-1A508920D0BCQ38696739-1D114C93-D4C9-45B5-9634-305163F493DEQ38722877-9339ECA0-0C5E-48E4-860D-C1AA8743DD1DQ39512185-13EBCF05-1BE1-40A2-86AC-21307D865654Q39529811-28B10253-174A-4313-87A4-077304301704Q39552291-2DB15F25-F916-4197-A47C-ACC92FE09D9AQ39559499-3808BF3B-9AD0-48EA-8237-F0B7BB976BACQ39935044-B8DC5A60-8373-4005-94A1-09F16C58710EQ40533491-F1A8E61C-BE82-46BB-A44F-1D7EC9526CC8Q42209635-BE5F6B1E-B6A6-4CAB-8374-C350B8D67A3CQ42762222-7BC1A4B1-9962-4637-B556-D1494521058CQ43253511-E1F42964-F89C-42CC-AFF0-1841D766AE39Q44661143-635A78D0-2C96-4854-8F5C-8F4313252ADDQ45932863-656D4E85-F18F-4A2B-BB4C-EE2EE9A376A3Q46684356-22AE4E16-8DE3-40DC-A86A-73BE090B19D9Q47806075-3F491563-FF76-40A0-B18C-181BA2B1FD5DQ48189196-97E555B8-CADD-48DD-9A44-8273194EBBDBQ48295687-2529EF9D-C431-4189-9008-340D2F0AD05AQ48316900-BE8D7E2F-4756-4356-95F6-0C98EA689460Q50902061-132C0C72-6EA4-44EC-92BB-3424F4D3ED17Q55098217-7115D55E-749B-499F-A480-DE27996F2DF3Q55263067-F3263A0C-BA5B-4234-801B-2731894A75E6Q57185723-25A99A0F-DB48-458F-A07D-FFE7CECEC5D4Q57757444-69928AE3-7801-4FA6-997A-8BD2D6EE6F34Q57757464-652A2E82-E4F3-48DB-8DDA-FDE290F85B58Q57757710-C5DAE250-CBC6-45C8-9B95-D72D261B51DEQ57757715-8FEAFB6C-21AB-43E7-AA8A-C217E428C4D1Q62863996-A13E3E75-B403-4E6F-B5BB-F146BDF829B4Q64230471-6E7CAD61-E8EE-46A7-9E64-A094AC6023E5Q90273231-6DB36591-B93C-4343-A97D-528A3F29E4AEQ90366016-067A9FA2-C075-4297-86F5-0D90B233D1F3Q92324162-4C7F7F6A-4040-493C-B6A6-EE26D53EBC0AQ92756458-03321CFC-E584-44CC-A01D-A76613DA9402Q93124250-9DBBB13D-7D68-43E5-9C28-7299D7B54FF9
P50
description
hulumtuese
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Elisabeth von Guggenberg
@ast
Elisabeth von Guggenberg
@en
Elisabeth von Guggenberg
@es
Elisabeth von Guggenberg
@nl
type
label
Elisabeth von Guggenberg
@ast
Elisabeth von Guggenberg
@en
Elisabeth von Guggenberg
@es
Elisabeth von Guggenberg
@nl
prefLabel
Elisabeth von Guggenberg
@ast
Elisabeth von Guggenberg
@en
Elisabeth von Guggenberg
@es
Elisabeth von Guggenberg
@nl
P106
P108
P21
P31
P496
0000-0003-4944-4705